Vaccitech

IPO

Guiding the immune system to cure disease

Oxford, United Kingdom · Founded 2016 · $206.4M raised

Headquarters
Oxford
Employees
51–200
Founded
2016
Business Model
B2B
Total Funding
$206.4M
Last Round
$168.0M Series BMar 2021
Rounds
3

About

Barinthus Biotherapeutics is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. Its pipeline is built around four proprietary platform technologies, ChAdOx, MVA, SNAP-TI, and SNAP-CI, and advances five product candidates including VTP-300 for chronic HBV infection, VTP-1000 for celiac disease, and VTP-850 for recurrent prostate cancer. Helping people living with serious diseases and their families is the guiding principle at the heart of Barinthus Biotherapeutics.

Summary

Vaccitech is a Biotech company based in Oxford, United Kingdom, founded in 2016. It has raised $206.4M in total across 3 rounds, most recently a $168.0M Series B round in Mar 2021. Investors include M&G Investments, GV and Sequoia China.

Tech & App Stack

5 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

IPOMay 2021
$110.5M

Sign up to see all 4 rounds

Seed through IPO — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Vaccitech on Indexed.vc
<a href="https://indexed.vc/companies/vaccitech"><img src="https://indexed.vc/api/badge/company/vaccitech" alt="Vaccitech on Indexed.vc" width="260" height="76" /></a>